



INFORMATION ONLY

Ondexxya (andexanet alfa) Listing Decision

Customer Letter # 2024-21

2024-05-06

Ondexxya (andexanet alfa), indicated for adult patients treated with FXa inhibitors (rivaroxaban or apixaban) when rapid reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, was assessed through the review process for plasma protein and related products (PPRP). At this time, Ondexxya will not be listed on the Canadian Blood Services PPRP Formulary.

The decision not to list Ondexxya follows the receipt of the [final recommendation](#) from the Canadian Agency for Drugs and Technologies in Health (CADTH) not to reimburse. Subsequent discussions between the manufacturer and Canadian Blood Services led the manufacturer to decide not to negotiate, effectively concluding the process at this stage.

For further information, please refer to the formulary listing recommendation report accessible [here](#).

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program